Integra LifeSciences implanted the first Cadence® Total Ankle as part of a non-randomized, prospective, multi-center postmarket study.
The trial will evaluate 2-year implant survivorship, which will be further evaluated at 5 and 10 years post-op. All patients will receive the Cadence device.
Since initial clinical use in 2Q16, >350 Cadence procedures have been performed in seven countries, including Europe and the U.S.; this is an increase from 200 performed by the end of 1Q17. Key design features of Cadence include:
- Side-specific, anatomical tibial components, intended to avoid fibular impingement
- Side-specific, anatomical talar components, intended to minimize resected talar bone and preserve vascularity
- Highly crosslinked ultra-high molecular weight polyethylene (HXL UHMWPE) bearing insert components for improved wear, and patent pending-biased sagittal profile options to address subluxed talar anatomy
Sources: Integra LifeSciences; clinicaltrials.gov; ORTHOWORLD Inc.
Image courtesy of Integra LifeSciences
Integra LifeSciences implanted the first Cadence® Total Ankle as part of a non-randomized, prospective, multi-center postmarket study.
The trial will evaluate 2-year implant survivorship, which will be further evaluated at 5 and 10 years post-op. All patients will receive the Cadence device.
Since initial clinical use in 2Q16, >350...
Integra LifeSciences implanted the first Cadence® Total Ankle as part of a non-randomized, prospective, multi-center postmarket study.
The trial will evaluate 2-year implant survivorship, which will be further evaluated at 5 and 10 years post-op. All patients will receive the Cadence device.
Since initial clinical use in 2Q16, >350 Cadence procedures have been performed in seven countries, including Europe and the U.S.; this is an increase from 200 performed by the end of 1Q17. Key design features of Cadence include:
- Side-specific, anatomical tibial components, intended to avoid fibular impingement
- Side-specific, anatomical talar components, intended to minimize resected talar bone and preserve vascularity
- Highly crosslinked ultra-high molecular weight polyethylene (HXL UHMWPE) bearing insert components for improved wear, and patent pending-biased sagittal profile options to address subluxed talar anatomy
Sources: Integra LifeSciences; clinicaltrials.gov; ORTHOWORLD Inc.
Image courtesy of Integra LifeSciences
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.